Gastric Cancer | Clinical

September 11, 2022

New results from the DESTINY-Gastric02 study include responses, survival data for patients receiving trastuzumab deruxtecan for with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

September 10, 2022

ADP-A2M4CD8, an autologous T-cell therapy, showed promising antitumor activity in several solid tumor types including ovarian, gastric, and urothelial cancer.

June 17, 2022

John L. Marshall, MD, discusses the situations where patients could benefit from fam-trastuzumab deruxtecan-nxki as second-line treatment for locally advanced or metastatic HER2-positive gastric cancer.

May 23, 2022

Orphan drug designation has been granted by the FDA to XMT-2056 for the treatment of patients with gastric cancers.

May 09, 2022

John L. Marshall, MD, discusses of the adverse event profile of fam-trastuzumab deruxtecan-nxki in patients with locally advanced or metastatic HER2-positive gastric cancer.

April 22, 2022

CMG90 is the only drug in its class to have received fast-track status to date. Prior to its fast track status, the drug was granted orphan drug designation by the FDA.

April 20, 2022

Bassel El-Rayes, MD, discusses how he approaches second-line therapy for patients with HER2-positive gastric cancer.

March 28, 2022

During a debate at the Gastrointestinal Cancers Symposium, Florian Lordick, MD, argued that knowledge of PD-L1 expression level was needed before starting immune checkpoint inhibitor therapy. He was challenged by Aaron James Scott, MD, who argued that knowledge of PD-L1 is not necessary before initiating immune checkpoint inhibitor therapy.

March 25, 2022

John Marshall, MD, discusses the DESTINY-Gastric01 study of fam-trastuzumab deruxtecan-nxki in patients with locally advanced or metastatic HER2-positive gastric cancer.

March 25, 2022

TST001 has shown to be safe in ongoing trials alone or in combination with chemotherapy and displayed encouraging anti-tumor activity signals in gastric cancer and other solid tumor patients expressing CLDN18.2.